Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.

被引：0
|
作者：
Shouval, D
Lai, CL
Cheinquer, H
Lok, A
DeHertogh, D
Wilber, R
Cross, A
Zink, R
Fernandes, L
机构：
[1] Hadassah Hebrew Univ Hosp, Jerusalem, Israel
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Univ Fed Rio Grande Sul, Porto Alegre, RS, Brazil
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Univ Connecticut, Farmington, CT USA
[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：728A / 728A
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF ENTECAVIR IN NUCLEOS(T)IDE NAiVE ASIANS WITH HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B: RESULTS FROM STUDIES ETV-022/027
    Gish, Robert G.
    Tsai, Naoky C. S. C.
    Pan, Calvin
    Kowdley, Kris V.
    Hu, Ke-Qin
    Lai, Ching Lung
    Chang, Ting-Tsung
    Han, Kwang-Hyub
    Cohen, David S.
    Tang, Hong
    Tong, Myron J.
    HEPATOLOGY, 2010, 52 (04) : 561A - 561A
  • [32] Entecavir (ETV) results in continued virologic and biochemical improvement through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R. G.
    LIVER INTERNATIONAL, 2006, 26 : 14 - 14
  • [33] The cost-effectiveness of entecavir in the longterm treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B patients in Sweden
    Cerri, K. H.
    Yuan, Y.
    Zammit, D. C.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A301
  • [34] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Lai, Ching-Lung
    Chang, Ting-Tsung
    Chao, You-Chen
    Tanwandee, Tawesak
    Thongsawat, Satawat
    Lee, Shou-Dong
    Angus, Peter
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A31 - A31
  • [35] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Lai, C. L.
    Cheinquer, H.
    Chang, T. T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S21 - S22
  • [36] Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027)
    Lai, Ching-Lung
    Chang, Ting-Tsung
    Chao, You-Chen
    Tanwandee, Tawesak
    Thongsawat, Satawat
    Lee, Shou-Dong
    Angus, Peter
    Zink, Richard
    Zhu, Jin
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A128 - A128
  • [37] IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAIVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS
    Bowden, S.
    Locarnini, S.
    Chang, T. -T.
    Chao, Y. -C.
    Han, K. -H.
    Gish, R. G.
    de Man, R.
    Llamoso, C.
    Tang, H.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S308 - S309
  • [38] Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S55 - S55
  • [39] Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Yurdaydin, C.
    Sollano, J.
    Hadziyannis, S.
    Kaymakoglu, S.
    Sherman, M.
    Brett-Smith, H.
    Vaughan, J.
    Hindes, R. G.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S36 - S36
  • [40] Entecavir results in continued virologic and biochemical improvement and HBeAg Seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)
    Sherman, Morris
    Martin, Paul
    Lee, William M.
    Yurdaydin, Cihan
    Sollano, Jose D.
    Vaughan, James
    Hindes, Robert G.
    GASTROENTEROLOGY, 2006, 130 (04) : A765 - A765
12345